Clinical Trial: A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naive and Biologic-naive Systemic Lupus Erythematosus

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07430306) titled 'A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naive and Biologic-naive Systemic Lupus Erythematosus' on Feb. 02.

Brief Summary: The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment.

Patients will be naive to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC ta...